SCHEMBL20005704

SCHEMBL20005704

S=C(NC1CCCC1)N1CCC(c2ccccc2)C1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.64
NPC1 O15118 7/20 0.64
SMN1; SMN2 Q16637 6/20 0.60
GAA P10253 2/20 0.60
MAPT P10636 1/20 0.60
ALDH1A1 P00352 3/20 0.58
CNR1 P21554 1/20 0.54
CNR2 P34972 1/20 0.54
HTT P42858 3/20 0.53
LMNA P02545 1/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
TP53 P04637 1/20 0.52
PKM P14618 1/20 0.50
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20005707 0.99 NPC1 (0.62) RAB9ANPC1SMN1; SMN2GAAMAPT
SCHEMBL20005708 0.95 RAB9A (0.65) RAB9ANPC1SMN1; SMN2GAAMAPT
SCHEMBL19995523 0.82 RAB9A (0.63) RAB9ANPC1SMN1; SMN2GAAMAPT
SCHEMBL19995974 0.82 RAB9A (0.63) RAB9ANPC1SMN1; SMN2GAAMAPT
SCHEMBL20005705 0.79 RAB9A (0.60) RAB9ANPC1SMN1; SMN2GAAMAPT
SCHEMBL23220399 0.78 RAB9A (0.61) RAB9ANPC1SMN1; SMN2GAAMAPT
SCHEMBL23951675 0.77 KMT2A (0.67) RAB9ANPC1SMN1; SMN2GAAMAPT
SCHEMBL19995815 0.76 RAB9A (0.56) RAB9ANPC1SMN1; SMN2GAAMAPT
SCHEMBL20005696 0.76 RAB9A (0.56) RAB9ANPC1SMN1; SMN2GAAMAPT
SCHEMBL19995564 0.76 RAB9A (0.56) RAB9ANPC1SMN1; SMN2GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017523-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2022-01-20 US disclosed
US-10975083-B2 Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors BIAL—PORTELA & CA, S.A. (PT) 2021-04-13 US disclosed
WO-2018056854-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS BIAL - PORTELA & Cª, S.A. (PT) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017523-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS DBH, SLC6A3, SLC6A2 RAB9A 943/4885NPC1 244/4885SMN1; SMN2 1617/4885
US-10975083-B2 Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors DBH, SLC6A3, SLC6A2 RAB9A 967/4885NPC1 271/4885SMN1; SMN2 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.